Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials

The National Institutes of Health (NIH), through its National Institute on Aging (NIA), has forecasted a grant opportunity titled "Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials." This grant is being offered under opportunity number FOR-RFA-AG-26-019, with funding anticipated to begin in the fiscal year 2026. The purpose of this funding opportunity is to support the development and implementation of multi-site clinical trials ranging from Phase Ib to Phase III. These trials will evaluate pharmacological and non-pharmacological interventions aimed at preventing, delaying, or alleviating symptoms associated with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). Projects will be carried out using the established infrastructure of the Alzheimer's Clinical Trials Consortium (ACTC), which is designed to streamline trial coordination and management. The ACTC serves as a collaborative network, and applicants will work in partnership with the NIA and ACTC leadership. This collaboration involves guidance and oversight from NIA and ACTC, ensuring that trial proposals align with scientific goals and operational capabilities of the consortium. Through this funding opportunity, the NIA seeks to advance the testing of promising interventions that address cognitive and neuropsychiatric changes tied to aging and AD/ADRD. Projects can target a wide spectrum of disease stages—from presymptomatic phases to advanced conditions. The NOFO (Notice of Funding Opportunity) associated with this forecast will utilize the R01 activity code, which supports discrete, specified research projects. As this opportunity is currently a forecast, applications are not yet being accepted. The estimated posting date for the official application is August 1, 2025, with applications due by October 5, 2025. Awards are expected to be made by July 1, 2026, and projects may commence on the same date. Interested researchers and institutions are encouraged to begin developing their proposals and forming partnerships now in preparation for the application window. Although no pre-application deadlines or question submission windows are specified, the advance notice aims to provide sufficient time for meaningful planning and collaboration. Funding details such as the total program amount, award floor, and ceiling are not yet specified in the forecast. Matching funds are not required for this opportunity, simplifying access for a broader range of applicants. A range of organizations are eligible to apply, including public and private institutions of higher education, nonprofits with 501(c)(3) status (excluding educational institutions), small and for-profit businesses, tribal governments and organizations, independent school districts, public housing authorities, and various levels of government. This broad eligibility framework supports interdisciplinary and cross-sector collaboration in aging and dementia research. The funding opportunity is administered by the National Institute on Aging. The designated contact for inquiries is Dr. Laurie Ryan, who can be reached at 301-496-9350 or via email at ryanl@mail.nih.gov. Researchers are encouraged to initiate communication with Dr. Ryan or the ACTC leadership to ensure alignment between their trial concepts and the objectives of this funding initiative. This proactive engagement will be essential for crafting competitive proposals aligned with the expectations and capacities of the ACTC framework. Although there is no indication that this opportunity is recurring, potential applicants are advised to monitor updates after the estimated award period. The inclusion of a detailed estimated timeline provides sufficient preparation window for applicants to align scientific, administrative, and collaborative resources for submission.